ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
11 hedge funds and large institutions have $1.35M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 2 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
50% more capital invested
Capital invested by funds: $901K → $1.35M (+$448K)
5.94% more ownership
Funds ownership: 7.26% → 13.2% (+5.9%)
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$475K |
| 2 |
Jane Street
New York
|
+$235K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$11.1K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$3.53K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$3.45K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$20.4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$10.3K |
| 3 |
SWA
SOA Wealth Advisors
New York
|
-$2.24K |
| 4 |
CPA
Clear Point Advisors
Melville,
New York
|
-$403 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $550K | +$475K | +33,659 | +305% |
|
2
Focus Partners Wealth
Boston,
Massachusetts
| $460K | +$311 | +22 | +0.1% |
|
|
3
Jane Street
New York
| $205K | +$235K | +16,614 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $56.8K | -$10.3K | -731 | -14% |
|
|
5
Morgan Stanley
New York
| $44.3K | -$20.4K | -1,443 | -29% |
|
|
6
Osaic Holdings
Scottsdale,
Arizona
| $12.3K | +$11.1K | +786 | +373% |
|
|
BBPWM
7
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| $8.9K | – | – | – |
|
|
8
Royal Bank of Canada
Toronto,
Ontario, Canada
| $4K | +$3.45K | +244 | +375% |
|
|
NFSG
9
Newbridge Financial Services Group
Boca Raton,
Florida
| $3.69K | – | – | – |
|
|
10
Wells Fargo
San Francisco,
California
| $3.08K | +$3.53K | +250 | New |
|
|
NA
11
NewEdge Advisors
New Orleans,
Louisiana
| $1.85K | +$706 | +50 | +50% |
|
|
SWA
12
SOA Wealth Advisors
New York
| – | -$2.24K | -150 | Closed |
|
|
CPA
13
Clear Point Advisors
Melville,
New York
| – | -$403 | -27 | Closed |
|
CNCR Hedge Fund Activity: Q4 2024 in Review
11 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q4 2024, worth a combined $1.35M — up 50% from $901K a quarter earlier.
Fund positioning in CNCR was balanced in Q4 2024: 2 funds opened new positions, 2 closed out, 5 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $475K. The largest seller was Morgan Stanley, cutting an estimated $20.4K.
- 11 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $1.35M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q4 2024, up 50% quarter-over-quarter.
- 2 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q4 2024 and 2 closed out, a net change of 0 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q4 2024 was Susquehanna International Group, an estimated $475K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q4 2024 was Morgan Stanley, an estimated $20.4K sold.
Based on aggregated 13F filings for Q4 2024.